TBPH FY 2024 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$716M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$64M+12.1% YoY

Gross Profit

$64M100.0% margin

Operating Income

-$47M-72.9% margin

Net Income

-$56M-87.6% margin

EPS (Diluted)

$-1.15

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$354M

Total Liabilities

$179M

Stockholders' Equity

$176M

Cash & Equivalents

$38M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$64M	$57M	+12.1%
Gross Profit	$64M	$17M	+283.2%
Operating Income	-$47M	-$56M	+16.2%
Net Income	-$56M	-$55M	-2.2%